Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

Javier Cortés

International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona

Kevin Punie

Medical Oncology, Oncology Center Antwerp, Ziekenhuis aan de Stroom, Antwerp, Belgium

Carlos Barrios

Latin American Cooperative Oncology Group, Porto Alegre, Brazil

Sara A. Hurvitz

Department of Medicine, University of Washington Medicine, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle

Andreas Schneeweiss

National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany

Joohyuk Sohn

Yonsei Cancer Center, Seoul, South Korea

Eriko Tokunaga

National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Adam Brufsky

Hillman Cancer Center, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh

Yeon Hee Park

Binghe Xu

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

Roberto Hegg

University of São Paulo, São Paulo

Mafalda Oliveira

Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona

Alessandra Fabi

Precision Medicine Unit in Senology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome

Natalya Vaksman

Gilead Sciences, Foster City, CA

Theresa Valdez

Gilead Sciences, Foster City, CA

Xinrui Zhang

Gilead Sciences, Foster City, CA

Catherine Lai

Gilead Sciences, Foster City, CA

Sara M. Tolaney

Department of Medical Oncology, Dana-Farber Cancer Institute